Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Steve Randall

Interventional Pain Medicine Midwest City, OK Medical Doctor

NPI 1902078298 CMS profile 358200

1732 S Sooner Rd, Midwest City, OK 73110

Open in the dashboard

General payments

$6,034

110 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Steve Randall of Midwest City, OK is reported in the CMS Open Payments database as having received $6,034 across 110 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 61st percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $284 9
2024 General $261 8
2023 General $248 6
2022 General $2,146 12
2021 General $1,305 14
2020 General $1,444 14
2019 General $346 47

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Steve Randall
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Steve Randall were reported at $284. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Steve Randall Interventional Pain Medicine median Middle half National median
2019 $346 $684 $216–$2,079 $163
2020 $1,444 $382 $122–$1,109 $114
2021 $1,305 $552 $167–$1,554 $132
2022 $2,146 $605 $187–$1,924 $149
2023 $248 $671 $195–$1,915 $160
2024 $261 $684 $206–$1,837 $164
2025 $284 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. SurGenTec $1,743 2 payments
  2. Stryker Corporation $977 4 payments
  3. Southern Spine, LLC $962 1 payment
  4. Nevro Corp. $604 20 payments
  5. Vertos Medical, Inc. $250 2 payments
  6. Medtronic, Inc. $246 6 payments
  7. Medtronic USA, Inc. $190 5 payments
  8. Merz North America, Inc. $150 1 payment
  9. Horizon Therapeutics plc $109 35 payments
  10. Spinal Simplicity, LLC $100 4 payments
  11. Other $705 30 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,511 74 payments
  2. Travel and Lodging $2,466 2 payments
  3. Education $1,057 34 payments
Products named General payments · program years 2019–2025
  1. ION Facet Screw $1,743 2 payments
  2. SPINEJACK $917 2 payments
  3. Omnia $308 10 payments
  4. mild Device Kit $250 2 payments
  5. Senza Spinal Cord Stimulator $233 7 payments
  6. KYPHON Balloon Kyphoplasty Neuro Pain (includes Interventional) $190 5 payments
  7. PENNSAID $104 34 payments
  8. HA MINUTEMAN G3-R $89 3 payments
  9. Senza Spinal Cord Stimulator $85 3 payments
  10. KYPHON Balloon Kyphoplasty Neuro Pain (includes Interventional) $82 1 payment
  11. Other $901 43 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 35 drugs

Part D claims

6,205

Median for Interventional Pain Management: 1,220

Drug cost

$229,119

Median for Interventional Pain Management: $39,344

Branded share of claims

52%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 1,124 $64,770
Oxycontin Oxycodone Hcl Brand 49 $50,177
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 1,688 $42,020
Oxycodone Hcl Generic 622 $13,826
Xtampza Er Oxycodone Myristate Brand 18 $10,999
Buprenorphine Generic 44 $8,110
Gabapentin Generic 541 $5,878
Morphine Sulfate Er Morphine Sulfate Brand 185 $5,260
Pregabalin Generic 262 $4,626
Fentanyl Generic 41 $3,031

The 10 drugs with the highest cost, of 35 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 60 billing codes

Paid by Medicare

$438,426

Of which drugs: $24

Medicare patients

402

Average age 72

Services billed

2,017

238 women, 164 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 43%
Diabetes 36%
Depression 32%
Chronic kidney disease 26%
COPD 26%
Heart failure 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 19 20 $2

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

110 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Oklahoma

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record